Laryngeal cancer medical therapy: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
=== Chemotherapy: === | === Chemotherapy: === | ||
[[Chemotherapy]] consists of two phases<ref name="pmid14645636">{{cite journal |vauthors=Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J |title=Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer |journal=N. Engl. J. Med. |volume=349 |issue=22 |pages=2091–8 |date=November 2003 |pmid=14645636 |doi=10.1056/NEJMoa031317 |url=}}</ref> | [[Chemotherapy]] consists of two phases<ref name="pmid14645636">{{cite journal |vauthors=Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J |title=Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer |journal=N. Engl. J. Med. |volume=349 |issue=22 |pages=2091–8 |date=November 2003 |pmid=14645636 |doi=10.1056/NEJMoa031317 |url=}}</ref><ref name="pmid23182993">{{cite journal |vauthors=Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS |title=Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer |journal=J. Clin. Oncol. |volume=31 |issue=7 |pages=845–52 |date=March 2013 |pmid=23182993 |pmc=3577950 |doi=10.1200/JCO.2012.43.6097 |url=}}</ref> | ||
'''Induction''': Three cycles of continuous infusion of [[cisplatin]] (100 mg/m2 on day 1) plus [[fluorouracil]] (1000 mg/m2/day ) followed by definitive [[radiation therapy]] in the induction phase | '''Induction''': Three cycles of continuous infusion of [[cisplatin]] (100 mg/m2 on day 1) plus [[fluorouracil]] (1000 mg/m2/day ) followed by definitive [[radiation therapy]] in the induction phase | ||
Revision as of 15:58, 11 January 2019
|
Laryngeal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Laryngeal cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Laryngeal cancer medical therapy |
|
Risk calculators and risk factors for Laryngeal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
The optimal therapy for laryngeal cancer depends on the stage at the time of diagnosis.
Medical Therapy
The medical therapy combined with radiation has largely replaced the surgical cure for laryngeal cancer depends on the stage at the time of diagnosis.[1] Multiple factors will be taken into account when considering treatment: [2][3]
- Laryngeal preservation
- Maintaining the airway
- Swallowing
- Speech
Chemotherapy:
Chemotherapy consists of two phases[4][5]
Induction: Three cycles of continuous infusion of cisplatin (100 mg/m2 on day 1) plus fluorouracil (1000 mg/m2/day ) followed by definitive radiation therapy in the induction phase
Concurrent: Cisplatin (100 mg/m2 on days 1, 22, and 43) with radiation therapy
Supportive Treatment
Many patients also need swallowing rehabilitation after treatment to help them adjust to the changes in the structure of the throat.
Radiation therapy
Radiotherapy may be of two types: External beam radiation therapy and internal radiation therapy.
- External radiation therapy to the thyroid or the pituitary gland may alter thyroid gland functioning
- Hyperfractionated radiation therapy and new types of radiation therapy are being studied in the treatment of laryngeal cancer
References
- ↑ Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, Ito J (February 2007). "Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years". Acta Otolaryngol Suppl (557): 62–5. doi:10.1080/00016480601067990. PMID 17453448.
- ↑ Lefebvre JL, Ang KK (April 2009). "Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary". Int. J. Radiat. Oncol. Biol. Phys. 73 (5): 1293–303. doi:10.1016/j.ijrobp.2008.10.047. PMID 19306746.
- ↑ Lefebvre JL, Ang KK (April 2009). "Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary". Head Neck. 31 (4): 429–41. doi:10.1002/hed.21081. PMID 19283793.
- ↑ Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (November 2003). "Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer". N. Engl. J. Med. 349 (22): 2091–8. doi:10.1056/NEJMoa031317. PMID 14645636.
- ↑ Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (March 2013). "Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer". J. Clin. Oncol. 31 (7): 845–52. doi:10.1200/JCO.2012.43.6097. PMC 3577950. PMID 23182993.